Journal of Current Ophthalmology最新文献

{"title":"How to Rescue of the Dislocated XEN^® Gel Stent: A New Surgical Approach on XEN Dislocation and Narrative Review.","authors":"Vincenzo Marchese, Viviana Randazzo, Rosanna Badalamenti, Marco Anastasi","doi":"10.4103/joco.joco_146_24","DOIUrl":"10.4103/joco.joco_146_24","url":null,"abstract":"<p><strong>Purpose: </strong>To introduce a novel surgical technique for repositioning a dislocated XEN63^® gel stent in patients with open-angle glaucoma, to synthesize contemporary findings on complications associated with stent dislocation, and to comment on related management strategies.</p><p><strong>Methods: </strong>A 75-year-old male with primary open-angle glaucoma experiencing XEN63 dislocation underwent this new surgical procedure. Key steps included identifying the scleral leakage site with Trypan Blue, performing precise scleral incisions, and careful stent repositioning. A mini-review on XEN dislocation was conducted through literature searches using PubMed, Embase, Medline, Web of Science, and Google Scholar, focusing on causes, complications, and management strategies. Relevant studies were selected based on specific inclusion criteria and a consensus process involving multiple reviewers.</p><p><strong>Results: </strong>The technique successfully repositioned the stent, with postoperative recovery indicating normal intraocular pressure and correct stent positioning. Initial postsurgery assessments confirmed stent functionality and correct placement. Pathophysiological mechanisms related to dislocation, type of dislocation, and relative management was also presented summarizing the findings based on current literature.</p><p><strong>Conclusions: </strong>The study presents an effective, conservative management method for repositioning dislocated XEN63 gel stents using an ab externo approach. This technique offers a less traumatic alternative to current practices by avoiding the need for additional devices or scleral pocket creation. The accompanying mini-review provides a comprehensive overview of XEN dislocation, enhancing the strategy for managing such complications. Further research, including broader case series or comparative studies, is essential to solidify these findings.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"444-452"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sudden Painful Proptosis following Orbital Evisceration: Early Implant Hemorrhage in the Anophthalmic Socket.","authors":"Mehmet Serhat Mangan, Yusuf Ziya Sahinoglu","doi":"10.4103/joco.joco_117_24","DOIUrl":"10.4103/joco.joco_117_24","url":null,"abstract":"<p><strong>Purpose: </strong>To report a case of early orbital hemorrhage following four-petal evisceration and highlighting the clinical presentation, diagnostic process, and surgical management.</p><p><strong>Methods: </strong>A 49-year-old male patient, with a history of chronic renal insufficiency on renal replacement therapy and anticoagulation treatment, presented with sudden painful proptosis 1 week after four-petal evisceration. Orbital magnetic resonance imaging revealed a hyperintense area suggestive of hemorrhage around the implant. Initial management involved intravenous steroid therapy to alleviate symptoms.</p><p><strong>Results: </strong>Despite the administration of steroids, the patient's proptosis and associated symptoms persisted. This led to the decision to perform surgical intervention. The surgical procedure encompassed the removal of the silicone implant, evacuation of the hemorrhage, and subsequently reinsertion of the same implant. Postoperatively, the patient's symptoms improved significantly.</p><p><strong>Conclusions: </strong>To our knowledge, this report represents the first case of early orbital hemorrhage developed following four-petal evisceration. This case underscores the potential for the development of early orbital hemorrhage following four-petal evisceration. Prompt recognition and appropriate surgical intervention are crucial for the management of the hemorrhage and preserving orbital function.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"468-471"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Nebulized Midazolam versus Oral Midazolam as Sedative Premedication in Pediatric Surgeries.","authors":"Abbas Ostadalipour, Anahid Maleki, Bita Malekianzadeh, Motahhareh Sadeghi, Alireza Takzare, Nima Nazari, Sumaiya Zahra, Armin Sahba, Parisa Kianpour, Saghar Samimi","doi":"10.4103/joco.joco_23_24","DOIUrl":"10.4103/joco.joco_23_24","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effectiveness of midazolam premedication administered through nebulization and orally as premedication in pediatric anesthesia in ophthalmic surgeries.</p><p><strong>Methods: </strong>In this randomized controlled double-blind trial, 70 patients scheduled for strabismus surgery were enrolled and divided into two groups. Group O (oral, <i>n</i> = 32) received 0.5 mg/kg oral midazolam and Group N (nebulized, <i>n</i> = 33) received 0.5 mg/kg midazolam through nebulization. Our outcomes included satisfactory sedation of patients, parental separation anxiety, mask acceptance scores, and perioperative hemodynamics up to 30 min postpremedication.</p><p><strong>Results: </strong>A significant difference in oxygen saturation (SpO₂) at the 30^th min emerged between nebulized and oral midazolam (<i>P</i> = 0.006). Ramsay Sedation scores within 30 min demonstrated comparable sedation levels between Groups N and O. Face mask acceptance scores were excellent in both groups, with no significant differences. Parental separation anxiety scores and the mask acceptance score at the 30^th min revealed no statistically significant differences at various time points (<i>P</i> > 0.05).</p><p><strong>Conclusions: </strong>In pediatric patients undergoing ophthalmic surgeries, nebulized midazolam is as effective as oral midazolam for sedation. The nebulized form is better tolerated and results in significantly improved SpO₂ levels 30 min after administration. These findings indicate that nebulized midazolam is a safe and effective alternative to oral midazolam for sedative premedication in young children.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"413-418"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical Coherence Tomography Angiography Vessel Density in Healthy, Pseudoexfoliation Syndrome and Exfoliative Glaucoma: Diagnostic Accuracy and Relationship with Structural Parameters.","authors":"Asma Khallouli, Zeineb Kallel, Maroua Anane, Racem Choura, Nourhen Aidi, Afef Maalej","doi":"10.4103/joco.joco_252_24","DOIUrl":"10.4103/joco.joco_252_24","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the diagnostic accuracy and relationship between structural and vascular measurements in pseudoexfoliation syndrome (PEX) and pseudoexfoliative glaucoma (GEX).</p><p><strong>Methods: </strong>Observational, case-control, and monocentric study conducted from March 2022 to April 2023. The study population comprised 153 eyes from 83 individuals divided into three groups: healthy (49), PEX (51), and GEX (53), with healthy subjects randomly selected from a cohort of nonglaucomatous patients. Structural parameters, including ganglion cell complex (GCC) and retinal nerve fiber layer (RNFL) were measured using spectral domain-optical coherence tomography (OCT). Vascular parameters were obtained from papillary and macular scans through OCT-angiography (OCT-A). The papillary whole-image vessel density (pWiVD), circumpapillary vessel density (cpVD), papillary vessel density (pVD), vessel densities in the superior, temporal, inferior, and nasal quadrants, as well as the macular WiVD, and the parafoveal and perifoveal vessel densities were measured. Structural parameters involved mean RNFL, superior, temporal, inferior, and nasal quadrant RNFL thicknesses, mean, inferior, and superior GCC thicknesses.</p><p><strong>Results: </strong>The analysis of OCT-A parameters revealed a significant decrease in all vascular densities measured in the papillary region between the GEX and PEX groups and between the PEX and control groups, except for the pVD, which was comparable between the latter 2 groups (<i>P</i> = 0.051). At the level of the macular region, we found a significant decrease in the vascular densities of the superficial plexus, more pronounced in the parafoveal region, in the GEX group compared to the PEX group and in the PEX group compared to the control group. No difference was noted in the deep vascular plexus. Strong correlations were noted between cpVD and average RNFL (<i>r</i> = 0.83), superficial parafoveal vessel density and GCC (<i>r</i> = 0.72), and between cpVD and superficial parafoveal vessel density (<i>r</i> = 0.84). Regression analyses showed cpVD (the area under the curve = 0.958) provided the best diagnostic value in distinguishing between PEX and GEX.</p><p><strong>Conclusions: </strong>cpVD is critical for detecting GEX, indicating that significant loss of peripapillary microvasculature with preserved structure strongly suggests GEX diagnosis.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"365-372"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Outcomes of Gonioscopy-Assisted Transluminal Trabeculotomy in Patients with Advanced Glaucoma.","authors":"Prakriti Yagnam Konuganti, Muralidhar Rajamani, Davinder S Grover, Craig John Chaya, Chitra Ramamurthy","doi":"10.4103/joco.joco_231_24","DOIUrl":"10.4103/joco.joco_231_24","url":null,"abstract":"<p><strong>Purpose: </strong>To review the results of gonioscopy-assisted transluminal trabeculotomy (GATT) in patients with advanced glaucoma. GATT has shown efficacy in mild to moderate cases of glaucoma. Its efficacy in advanced glaucoma is uncertain, though recent studies show promising short-term outcomes.</p><p><strong>Methods: </strong>A retrospective chart review of advanced glaucoma patients undergoing GATT with or without cataract surgery from January 2018 to April 2023 was conducted. Complete success was defined as intraocular pressure (IOP) <14 mmHg with ≥30% reduction from baseline (Criteria A) or IOP <18 mmHg and/or ≥20% reduction (Criteria B), without antiglaucoma medications. Qualified success was defined as attainment of the same with a maximum of 2 medications.</p><p><strong>Results: </strong>A total of 69 eyes from 60 patients (mean age, 61.2 ± 15.3 years) were included in the study. The mean IOP decreased from 24.9 ± 10.7 mmHg preoperatively to 12.1 ± 3.0 mmHg at 6 months postoperatively. At 6 months, the complete success rate (based on Criteria A) was 66.7%, with an overall success rate of 81.9%. By 1 year (<i>n</i> = 52), these rates were 51.9% and 65.4%, respectively. Using Criteria B, the complete success rate was 74.2%, and the overall success rate was 95.4% at 6 months, decreasing to 57.7% and 82.7% at 1 year. Patients who had used antiglaucoma medications for <2 weeks before surgery showed significantly higher success rates at both 6 months (<i>P</i> = 0.01) and 1 year (<i>P</i> = 0.019). Combining GATT with cataract surgery also improved success rates at 6 months (<i>P</i> = 0.005). In addition, six eyes with previously failed trabeculectomy achieved success at 6 months, with five remaining successful at 1 year. Three eyes experienced delayed bleeds with an IOP spike, all of which met failure criteria during the follow-up.</p><p><strong>Conclusions: </strong>GATT demonstrates encouraging short-term outcomes in advanced glaucoma, particularly in treatment-naïve patients and those undergoing combined cataract surgery. However, delayed bleeds can lead to IOP spikes and treatment failure. GATT may be considered as a viable surgical option in treatment naïve patients with advanced glaucoma. Its efficacy is bolstered when combined with cataract surgery.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"373-380"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclodialysis Cleft following Intravitreal Injection; Case Report.","authors":"Luis J Haddock, Arindel S R Maharaj, Jorge A Fortun, Alireza Mahmoudi","doi":"10.4103/joco.joco_104_25","DOIUrl":"10.4103/joco.joco_104_25","url":null,"abstract":"<p><strong>Purpose: </strong>To report an uncommon complication arising from an intravitreal injection (IVI).</p><p><strong>Methods: </strong>This case describes ocular hypotony secondary to a cyclodialysis cleft following an IVI, including its management.</p><p><strong>Results: </strong>A 68-year-old male presented with a 5-month history of persistent hypotony and vision loss in the left eye following an intravitreal antivascular endothelial growth factor (anti-VEGF) injection. His history included rhegmatogenous retinal detachment in the right eye and chronic central serous chorioretinopathy with macular neovascularization in the left eye, treated with intravitreal anti-VEGF injections for 5 years. Clinical findings included best-corrected visual acuity (BCVA) of 20/1600 (right) and 20/150 (left), with intraocular pressure (IOP) of 16 mmHg (right) and 4 mmHg (left). Slit-lamp exam of the left eye revealed a deep pseudophakic anterior chamber, resolving vitreous hemorrhage, and chorioretinal folds without retinal breaks. Gonioscopy identified a suspected cyclodialysis cleft inferotemporally, which was confirmed by 50 MHz ultrasound biomicroscopy (UBM). The patient was treated with intraoperative argon laser photocoagulation (120 shots, 300 mW), targeting the cleft through a corneal incision. UBM, the next day, confirmed cleft closure and ciliary body reattachment. A transient IOP spike to 42 mmHg was medically controlled. Over the following weeks, IOP stabilized between 10 and 15 mmHg without medications, and optical coherence tomography showed resolution of chorioretinal folds and subretinal fluid. Final BCVA improved to 20/70 (left eye) and 20/800 (right eye postcataract surgery).</p><p><strong>Conclusion: </strong>This report underscores a rare complication of IVIs and highlights the critical role of UBM in achieving accurate diagnostic assessment.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"472-474"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy and Safety of Biosimilar Bevacizumab (Stivant^®) versus Reference Product (Avastin^®) in Prethreshold Type I Retinopathy of Prematurity.","authors":"Mojtaba Abrishami, Zohreh Golmohammadi, Nasser Shoeibi, Mohammad-Reza Ansari-Astaneh, Mehdi Sakhayi, Majid Abrishami, Seyedeh Maryam Hosseini, Elham Bakhtiari, Mehrdad Motamed Shariati","doi":"10.4103/joco.joco_178_24","DOIUrl":"10.4103/joco.joco_178_24","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of Stivant^® (biosimilar bevacizumab, CinnaGen, Iran) to Avastin^® (innovator bevacizumab, Genentech, South San Francisco, CA) in premature infants with prethreshold type I retinopathy of prematurity (ROP).</p><p><strong>Methods: </strong>Preterm infants with bilateral prethreshold type 1 ROP were enrolled in this nonrandomized contralateral clinical trial. Bilateral intravitreal bevacizumab (IVB) was administered, with Stivant^® injected in one eye and Avastin^® in the other. Patients were followed up weekly for 4 weeks, then biweekly until complete retinal vascularization. Efficacy was evaluated based on disease activity regression (plus disease regression) and complete retinal vascularization. Safety was assessed through the monitoring of adverse events such as uveitis and endophthalmitis.</p><p><strong>Results: </strong>Forty-four infants were included in the study. The mean age at IVB injection was 34.5 weeks. Complete retinal vascularization occurred at a mean age of 60.02 weeks for Stivant^® and 59.93 weeks for Avastin^® (<i>P</i> = 0.59). Five patients (11.3%) underwent bilateral laser photocoagulation as rescue treatment. Our results showed that Stivant^® was noninferior to Avastin^® in retinal vascularization progress. However, this study cannot make definitive noninferiority claims due to the sample size and its design as a pilot investigation. No cases of endophthalmitis or uveitis were reported.</p><p><strong>Conclusions: </strong>Stivant^® exhibited noninferiority to Avastin^® in efficacy and demonstrated a comparable safety profile in treating prethreshold type I ROP. A definite conclusion requires more extended studies with a larger sample size.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"407-412"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Learning: A Survey to Evaluate How Ophthalmologists Learn New Surgical Techniques.","authors":"Jee-Ah Sarah Oh, Stephen Ng, Jie Zhang, James McKelvie","doi":"10.4103/joco.joco_186_24","DOIUrl":"10.4103/joco.joco_186_24","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate ophthalmologists' attitudes and approaches to learning new surgical techniques.</p><p><strong>Methods: </strong>This cross-sectional, prospective study distributed an anonymous, voluntary web-based survey via email to surgeons of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO). The survey collected data on demographics, fellowship training, practice location, the number of trainee surgeons supervised, the impact of Coronavirus disease 2019, resources for surgical learning, and perceived barriers to learning and adopting new techniques. Multiple-choice, scaled response, and open-ended questions were used in the survey.</p><p><strong>Results: </strong>Seventy-five surveys were completed (7.1% of 1050 members). Multivariable analysis demonstrated that the number of new surgical techniques adopted over the preceding 5 years was associated with the number of trainee surgeons supervised (<i>P</i> = 0.003); membership of the New Zealand branch of RANZCO (<i>P</i> = 0.021); self-reported interest in innovation (<i>P</i> = 0.043); and inversely associated with the age of the surgeon (<i>P</i> = 0.002). YouTube was the most frequently used resource. It was used by 96% of respondents and rated the most useful resource by 95.8% of respondents. The two most frequent barriers to learning and adopting new surgical techniques were fear of adverse outcomes (90.7%) and having an existing technique with good outcomes (90.7%).</p><p><strong>Conclusions: </strong>This is the first study exploring how ophthalmologists learn new surgical techniques. The widespread use of YouTube for surgical learning highlights the opportunity for postgraduate colleges to create or post quality-controlled online video resources for their members.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"428-443"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmic Comorbidities in Patients with Chronic Plaque Psoriasis: A Hospital-Based Cross-Sectional Study of 100 Patients.","authors":"Kritika Katoch, Rattan Kumar Sharma, Vikram K Mahajan, Rajeev Tuli","doi":"10.4103/joco.joco_147_24","DOIUrl":"10.4103/joco.joco_147_24","url":null,"abstract":"<p><strong>Purpose: </strong>To study the characteristics of ophthalmic comorbidities in patients with chronic plaque psoriasis.</p><p><strong>Methods: </strong>We assessed the clinical and epidemiological attributes and characteristics of ophthalmic comorbidities of patients who had chronic plaque psoriasis for 15-25 years (mean ± standard deviation [SD], 3.9 ± 4.8 years). Out of 100 patients, 57 were males and 43 were females. In this cohort, the age range was from 19 to 77 years (mean ± SD, 41.8 ± 13.9 years). The severity of psoriasis was defined by the psoriasis area severity index (PASI) score as mild (PASI ≤6), moderate (PASI >6-12), or severe (PASI >12).</p><p><strong>Results: </strong>Psoriasis was mild in 77, moderate in 13, and severe in 10 patients, respectively. Three patients had asymmetric oligoarthritis. In a cohort of 100 patients, there were 23 patients with moderate-to-severe psoriasis and 77 patients with mild psoriasis. In the moderate-to-severe psoriasis group, 18 out of the 23 patients also had ophthalmic abnormalities. In the mild psoriasis group, 53 of 77 patients also had ophthalmic abnormalities. Itching (<i>n</i> = 12; psoriasis was mild in 7, moderate-to-severe in 5 patients), decreased vision (<i>n</i> = 12; psoriasis was mild in 10, moderate-to-severe in 2 patients), redness (<i>n</i> = 9; psoriasis was mild in 5, moderate-to-severe in 5 patients;), watering/discharge (<i>n</i> = 8; psoriasis was mild in 6, moderate-to-severe in 2 patients), and pain or burning (<i>n</i> = 6; psoriasis was mild in 4, moderate-to-severe in 2 patients) were commonly complained by 31 patients. The major ophthalmic comorbidities in order of frequency observed were keratoconjunctivitis sicca/dry eye (<i>n</i> = 41), blepharitis (<i>n =</i> 29), meibomian gland dysfunction (MGD) (<i>n =</i> 18), conjunctivitis (<i>n =</i> 10), corneal abnormalities (<i>n =</i> 13), cataract (<i>n =</i> 14), retention cyst (<i>n =</i> 2), and anterior uveitis in 2 patients (without psoriatic arthritis). Common corneal abnormalities were punctuate keratitis (<i>n =</i> 7), corneal opacities (<i>n =</i> 4), band-shaped keratopathy (<i>n =</i> 1), and superficial vascularization (<i>n =</i> 1). Posterior segment manifestations of arteriosclerotic changes (<i>n</i> = 4), media haze (<i>n</i> = 2), and macular degeneration (<i>n</i> = 1) were likely to be age-related.</p><p><strong>Conclusions: </strong>The ophthalmic comorbidities, such as blepharitis, MGD, conjunctivitis, keratoconjunctivitis sicca, corneal abnormalities, and presenile cataract, can occur in patients with psoriasis. These are largely asymptomatic and subtle findings that are often missed. They require an early consult to ophthalmology for appropriate management. The major limitations in this study are that it is a single-center, cross-sectional study design that has a low number of patients, lacks a healthy patient control group, and there is a lack of long-term follow-up.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"419-427"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous Platelet-Rich Plasma Injections for Treatment of Dry Eyes: A Pilot Study.","authors":"Anchal Tripathi, Avinash Mishra, Atul Bhirud, Mohini Agrawal, Vidhu Dhar Dangwal, Lav Pathak","doi":"10.4103/joco.joco_138_24","DOIUrl":"10.4103/joco.joco_138_24","url":null,"abstract":"<p><strong>Purpose: </strong>To study was to study the efficacy of autologous platelet-rich plasma injections (PRPi) in the treatment of dry eyes.</p><p><strong>Methods: </strong>This prospective, interventional study was conducted at a tertiary eye care center, India. One hundred and sixty eyes of 80 patients with newly diagnosed dry eyes were included. One eye received PRPi (cases = 80 eyes), and the other eye of the patient received a lubricating drop (control = 80 eyes). Cases who did not improve at 1-month follow-up (FU) were reinjected with PRP. The outcomes were measured on the basis of ocular surface disease index (OSDI), Schirmer's test (ST), noninvasive tear breakup time (NIBUT), tear meniscus height (TMH), and ocular surface staining (OSS) score done at baseline and 1-month, 2-month, 3-month, and 6-month FU.</p><p><strong>Results: </strong>Sixty cases showed a significant improvement in all the outcome measures at 1 month (<i>P</i> < 0.001), when compared to controls; whereas, 20 cases had to undergo repeat injections. On FU at 2 months, 16 cases (out of those 20 cases) showed a significant improvement (<i>P</i> < 0.05), while 4 cases still did not improve clinically at 3 months. All the outcome parameters (ST, NIBUT, TMH, and OSS and OSDI scores) maintained a significant improvement at 6-month FU, including those four cases (<i>P</i> < 0.001). All the patients were highly satisfied with the intervention.</p><p><strong>Conclusion: </strong>PRPi, as a monotherapy given on <i>pro-re-nata</i> basis, is a simple and efficacious modality of treatment in dry eyes, verified by improvement in subjective and objective tear film parameters.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"381-386"},"PeriodicalIF":0.9,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}